Insider Selling: Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Sells 1,995 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Justin Klee sold 1,995 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $13.89, for a total value of $27,710.55. Following the transaction, the chief executive officer directly owned 3,379,398 shares of the company’s stock, valued at approximately $46,939,838.22. The trade was a 0.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX traded up $2.25 during mid-day trading on Tuesday, reaching $16.55. The company had a trading volume of 4,418,477 shares, compared to its average volume of 1,376,666. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -9.19 and a beta of -0.31. The company’s 50 day simple moving average is $13.17 and its 200 day simple moving average is $11.75. Amylyx Pharmaceuticals, Inc. has a 1-year low of $2.60 and a 1-year high of $16.96.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.06. As a group, equities analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on AMLX shares. Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. HC Wainwright boosted their price target on Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Lifesci Capital raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Finally, Robert W. Baird boosted their target price on shares of Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC boosted its position in Amylyx Pharmaceuticals by 76.4% during the fourth quarter. SG Americas Securities LLC now owns 20,846 shares of the company’s stock valued at $252,000 after acquiring an additional 9,027 shares during the last quarter. Maven Securities LTD bought a new stake in shares of Amylyx Pharmaceuticals during the 3rd quarter valued at about $951,000. TCG Crossover Management LLC increased its holdings in Amylyx Pharmaceuticals by 5.0% in the third quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock worth $84,853,000 after purchasing an additional 300,000 shares in the last quarter. Dark Forest Capital Management LP bought a new stake in shares of Amylyx Pharmaceuticals in the 3rd quarter valued at $1,180,000. Finally, Verition Fund Management LLC acquired a new position in shares of Amylyx Pharmaceuticals during the 3rd quarter valued at $868,000. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.